BridgeMD
New treatment option for Kidney Disease, Chronic
Official title Diuretic Testing in Chronic Kidney Disease
ClinicalTrials.gov ID: NCT06841692
What this study is testing
- What it's testing
- The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are: Does a worse result of a diuretic test predict the progression of chronic kidney disease?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- for CKD people:
- CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit for Healthy people:
- eGFR within the expected range for age (a decline of 1 ml/min/1.73 m2 per year starting from age 40 is considered the normal age-related decline in...
You likely can't join if
- Known intolerance or allergy to the diuretics
- Current systemic chemotherapy for malignancy
- Kidney transplant recipient
- Use of calcineurin-inhibitors
- Life expectancy \< 12 months
- Current immunosuppressive treatment for glomerulonephritis
See the full eligibility criteria
- for CKD people:
- CKD stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) during the last outpatient visit for Healthy people:
- eGFR within the expected range for age (a decline of 1 ml/min/1.73 m2 per year starting from age 40 is considered the normal age-related decline in kidney function
- Known intolerance or allergy to the diuretics
- Current systemic chemotherapy for malignancy
- Kidney transplant recipient
- Use of calcineurin-inhibitors
- Life expectancy \< 12 months
- Current immunosuppressive treatment for glomerulonephritis
- Incapacitated people or people who are deemed unfit to adequately adhere to instructions from the research team
- Hypokalemia or hyperkalemia (K+ \ 5.5 mmol/L) at inclusion visit
- Hypo- or hypernatremia (Na+ \ 150mmol/L) at inclusion visit
- Inherited tubulopathy as the cause of CKD
- Autosomal dominant polycystic or tubulointerstitial kidney disease causing CKD
- Clinically relevant heart failure (New York Heart Association class III or IV)
- Therapy-resistant hypertension, defined as systolic blood pressure \> 180mmHg at the inclusion visit
- Current treatment with inhibitors of Organic anion transporters: probenecid, pravastatin, cimetidine, cephalosporins, acetazolamide [22]
- Active hepatitis during last outpatient visit
- Liver cirrhosis in advanced stage (Child-Pugh B or C)
- Active drug- or alcohol abuse
- Not being able to tolerate a 28-day washout of one of the drugs interfering with diuretic testing.
- Women who are pregnant, breastfeeding, or planning on becoming pregnant before the test day
The study team makes the final eligibility decision.
Where it's taking place
- Rotterdam, South Holland, Netherlands
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rotterdam, South Holland, Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.